Gapping down
In reaction to disappointing earnings/guidance: CTP -14.6%, FFIV -13.7%, SLM -7.7%, XLNX -7.7%, SNDK -6.5%, (also expands stock repurchase program by $2.5 bln), XRS -3.6%, FCS -3.5%, DLB -2.5%, DFS -2.4%, AXP -2%, RY -1.8%, IAG -1.3%, VZ -0.6%
Select EU pharma names showing weakness: NVO -2.4%, NVS -2.3%, SHPG -2%, AZN -1.2%
Select metals/mining stocks trading lower: CLF -2%, AUY -1.9%, HMY -1.6%, EGO -1%, ABX -0.9%, NEM -0.9%, GDX -0.8%
Other news: OTIC -7.9% ( announces the launch of its proposed follow-on public offering of ~$75 mln of its common stock ), ASPX -6.1% ( announces 4.0 mln share offering), ALTR -3.5% (following XLNX results), XON -3.3% (prices 3,750,000 shares of common stock at $27.00 per share), KERX -2% (prices 9,166,667 shares at $12.00 per share), MDVN -2% (Medivation and Astellas Pharma announce topline results from the Phase 2 TERRAIN trial), CLDT -1.8% (priced its upsized public offering of 3.5 mln common shares at a per share public offering price of $30.00), BMRN -1.8% (prices 8,500,000 shares of common stock at price of $93.25 per share), PBYI -1.5% (prices 1 mln shares of its common stock at $190.00 per share), CSCO -1.3% ((Oracle CEO Larry Ellison's said Oracle's new generation of engineered systems will be 50% cheaper than current offerings, also may be on FFIV results), JNPR -1.1% (on FFIV results), TSL -0.9% (comments on ITC's final determination in anti-dumping duty and countervailing duty investigations)
Analyst comments: ARWR -5.2% (downgraded to Hold from Buy at Deutsche Bank), PCAR -0.6% (downgraded to Underperform at BMO Capital), FLR -0.5% (downgraded to Neutral from Buy at BofA/Merrill)
In reaction to disappointing earnings/guidance: CTP -14.6%, FFIV -13.7%, SLM -7.7%, XLNX -7.7%, SNDK -6.5%, (also expands stock repurchase program by $2.5 bln), XRS -3.6%, FCS -3.5%, DLB -2.5%, DFS -2.4%, AXP -2%, RY -1.8%, IAG -1.3%, VZ -0.6%
Select EU pharma names showing weakness: NVO -2.4%, NVS -2.3%, SHPG -2%, AZN -1.2%
Select metals/mining stocks trading lower: CLF -2%, AUY -1.9%, HMY -1.6%, EGO -1%, ABX -0.9%, NEM -0.9%, GDX -0.8%
Other news: OTIC -7.9% ( announces the launch of its proposed follow-on public offering of ~$75 mln of its common stock ), ASPX -6.1% ( announces 4.0 mln share offering), ALTR -3.5% (following XLNX results), XON -3.3% (prices 3,750,000 shares of common stock at $27.00 per share), KERX -2% (prices 9,166,667 shares at $12.00 per share), MDVN -2% (Medivation and Astellas Pharma announce topline results from the Phase 2 TERRAIN trial), CLDT -1.8% (priced its upsized public offering of 3.5 mln common shares at a per share public offering price of $30.00), BMRN -1.8% (prices 8,500,000 shares of common stock at price of $93.25 per share), PBYI -1.5% (prices 1 mln shares of its common stock at $190.00 per share), CSCO -1.3% ((Oracle CEO Larry Ellison's said Oracle's new generation of engineered systems will be 50% cheaper than current offerings, also may be on FFIV results), JNPR -1.1% (on FFIV results), TSL -0.9% (comments on ITC's final determination in anti-dumping duty and countervailing duty investigations)
Analyst comments: ARWR -5.2% (downgraded to Hold from Buy at Deutsche Bank), PCAR -0.6% (downgraded to Underperform at BMO Capital), FLR -0.5% (downgraded to Neutral from Buy at BofA/Merrill)